Cramer Bullish on Eli Lilly and Costco Despite Economic Fears

  cramer-bullish-on-eli-lilly-and-costco-despite-economic-fears.html
  Stocks and Investing on Mon, Feb 02nd, 2026 by CNBC
      Locale: UNITED STATES

Tuesday, February 3rd, 2026 - Despite ongoing macroeconomic anxieties surrounding interest rates, inflation, and recessionary fears, CNBC's Jim Cramer remains bullish on two key portfolio stocks: Eli Lilly (LLY) and Costco (COST). Speaking on "Squawk on the Street" Monday, Cramer highlighted recent developments that reinforce his confidence in the continued success of both companies. While market volatility persists, Cramer argues these two provide a compelling narrative of resilience and growth, diverging from the broader economic concerns.

Eli Lilly: Beyond Alzheimer's - A Pipeline Powerhouse

The primary catalyst for Cramer's continued support of Eli Lilly is the overwhelmingly positive preliminary assessment of donanemab, Lilly's investigational treatment for Alzheimer's disease, delivered by a key Food and Drug Administration (FDA) advisory panel on Friday. While FDA approval isn't automatic, the panel's favorable review significantly increases the probability of donanemab reaching the market. This potential breakthrough isn't simply about addressing a devastating disease; it's indicative of a broader trend within Eli Lilly.

"This isn't just about Alzheimer's drugs," Cramer emphasized. "It's about Eli Lilly's incredible pipeline, and it's about their ability to hit after hit." This "hitting streak" refers to Lilly's recent successes with other pharmaceuticals, notably Mounjaro and Zepbound, medications for diabetes and obesity respectively. These drugs have demonstrated remarkable efficacy and have rapidly gained market share, driving substantial revenue growth for the company. The anticipation surrounding donanemab builds upon this existing momentum and signals Lilly's capacity for sustained innovation.

The pharmaceutical industry is notoriously high-risk, high-reward. The development of new drugs is an expensive and lengthy process with no guarantee of success. However, Lilly has consistently demonstrated an ability to navigate these challenges and bring groundbreaking therapies to market. This track record, combined with a robust pipeline encompassing multiple therapeutic areas - including immunology, oncology, and neuroscience - positions the company for long-term growth. Analysts predict that if approved, donanemab could generate billions in annual revenue, further cementing Lilly's position as a leader in the pharmaceutical sector. Beyond donanemab, the company is also exploring other potential Alzheimer's treatments and expanding its research into other neurodegenerative diseases.

Costco: The Consumer Spending Thermometer

While Eli Lilly benefits from innovation within a highly regulated industry, Costco thrives on a different principle: consistent value and loyal customer base. The warehouse retailer recently reported strong sales figures and impressive inventory management, defying expectations amidst ongoing economic uncertainty. This performance, according to Cramer, makes Costco the "ultimate bellwether" for consumer behavior.

"Costco is the ultimate bellwether, and this report tells us that consumers are still feeling pretty good," Cramer stated. Despite rising prices and concerns about a potential recession, Costco's membership model fosters consistent spending. Members pay an annual fee for the privilege of accessing discounted goods, incentivizing them to consolidate their purchases at Costco. This creates a predictable revenue stream for the company, even during periods of economic slowdown.

Furthermore, Costco's efficient supply chain and bulk purchasing power allow it to offer competitive prices, attracting consumers seeking to stretch their budgets. The company has also demonstrated a keen ability to adapt to changing consumer preferences, expanding its offerings to include more organic products, private-label brands, and ancillary services like travel and optical care. Looking ahead, Costco is expected to continue expanding its physical footprint, both domestically and internationally, and investing in its e-commerce platform to cater to evolving consumer demands. The company's commitment to providing value, coupled with its strong brand loyalty, makes it a resilient investment even in challenging economic times.

A Portfolio Strategy for Uncertainty

Cramer's endorsement of both Eli Lilly and Costco highlights a strategy of diversification and a focus on companies with strong fundamentals. While macroeconomic factors undoubtedly influence market performance, Cramer believes that identifying companies with proven track records and promising growth prospects is crucial for building and maintaining a solid portfolio. Both Lilly and Costco represent companies that appear well-positioned to weather the storm and deliver consistent returns to investors, regardless of the broader economic landscape. Investors should, however, always conduct their own due diligence and consult with a financial advisor before making any investment decisions.